Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 4/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | UGT8 | Q16880 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27057084 | 0.79 | HSD17B10 (0.45) | PDE10AJAK3BTKMAP4K4CKS1B | |
| SCHEMBL4470860 | 0.78 | SYK (0.53) | ACACBSYKPDE10A | |
| SCHEMBL4471437 | 0.77 | PDE10A (0.50) | SYKPDE10AAURKAPDPK1AURKB | |
| SCHEMBL13334995 | 0.77 | CCR2 (0.53) | — | |
| SCHEMBL19754737 | 0.76 | CHRM4 (0.49) | ACACBSYKPDE10AJAK3BTK | |
| SCHEMBL13361915 | 0.76 | SYK (0.39) | ACACBSYKAURKAPDPK1AURKB | |
| SCHEMBL24244026 | 0.76 | ACACB (0.48) | ACACBSYKPDE10AJAK3BTK | |
| SCHEMBL29182903 | 0.76 | SUV39H2 (0.49) | SYKPDE10AJAK3BTKMAP4K4 | |
| SCHEMBL29182901 | 0.76 | SUV39H2 (0.49) | SYKPDE10AJAK3BTKMAP4K4 | |
| SCHEMBL18636734 | 0.74 | LMNA (0.53) | PDE10AAURKAPDPK1AURKBJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514562-B2 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | TRPV1, UTS2R, OPRL1 | ACACB 4799/4885SYK 3457/4885PDE10A 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.